Global Partners GLP
$42.13 −$1.13 (-2.61%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $42.13 0.00%
Open$43.01
Prev close$43.26
Day range$41.92 – $43.07
Volume80.4K
Market cap$1.43B
P/E (TTM)7.7
Dividend yield7.26%
GLP Stock News
Headlines matching Global Partners or the GLP ticker, most recent first.
- Accelerating global expansion! Hengrui Pharma licenses its oral GLP-1/GIP weight-loss drug to Novo-Nordisk A/S, with potential deal value reaching up to $2.6 billion. Mixed
- Hengrui Pharma Seals Up to US$2.6 Billion Global Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Drug
- Will GLP-1s Hurt Food Stocks? Assessing the Changing Consumer.
- Raymond James Initiates Global Partners(GLP.US) With Hold Rating
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES INU.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, ANDASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OFASC36 AND GLP-1R/G
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS SUBMITS TWO IND APPLICATIONS TO THE U.S. FDAFOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, A PEPTIDE AMYLIN RECEPTOR AGONIST,AND ASC36_35 FDC ONCE-MONTHLY INJECTION,A CO-FORMULATION OF ASC36 PLUS PEPTIDE GLP-1R
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR PHASE I STUDYOF ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, ASC35, FOR THE TREATMENT OF OBESITY
- Yinuos (688710): Nantong Yinuos' "High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform Expansion Project" has obtained NMPA GLP certification. Positive
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE II STUDY OFASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST, FOR THETREATMENT OF DIABETES
- Jiaze Renewables Corporation: Jiaze New Energy Co., Ltd. Simplified Equity Change Report (Information Discloser: GLP Renewable Energy Investment I Limited)
- Neutral Outlook on Magnum Ice Cream Co.: Soft Demand, Margin Pressure, and GLP-1 Risks Cap Near-Term Upside
- U.S. Regulators Warn GLP-1 Drugs Carry Possible Rare Blindness Risk -- WSJ
- Hims & Hers Struck a GLP-1 Deal With Lilly. Its Stock Is Rallying.
- Multiple GLP-1 injectables have been included in the National Reimbursement Drug List (NRDL) for the first time, including products from Pfizer and Innovent Biologics, for the treatment of type 2 diabetes in adults.
- Leading Novo Nordisk! China's first oral GLP-1 weight-loss drug has been approved and production has already begun ahead of schedule. Mixed
No comments yet — be the first to weigh in on GLP.
Sign in to join the discussion.